Evidence map›Paper›PMID 29705972›Full record

ArticleJIMD reports2018

P-Tau and Subunit c Mitochondrial ATP Synthase Accumulation in the Central Nervous System of a Woman with Hurler-Scheie Syndrome Treated with Enzyme Replacement Therapy for 12 Years.

Hiroshi Kobayashi, Masamichi Ariga, Yohei Sato, Masako Fujiwara, Nei Fukasawa, Takahiro Fukuda, Hiroyuki Takahashi, Masahiro Ikegami, Motomichi Kosuga, Torayuki Okuyama and 2 more

Open access · greenAbstract read
In one paragraph

Article in JIMD reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Pathogenesis of Mucopolysaccharidoses, an Update.International journal of molecular sciences · 2020
    Review
  4. Novel Enzyme Replacement Therapies for Neuropathic Mucopolysaccharidoses.International journal of molecular sciences · 2020
    Review
  5. Recent trends in mucopolysaccharidosis research.Journal of human genetics · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Hiroshi KobayashiDivision of Gene Therapy, Research Center of Medical Sciences, Jikei University School of Medicine, Tokyo, Japan. hrkb@jikei.ac.jp.
Masamichi ArigaDivision of Gene Therapy, Research Center of Medical Sciences, Jikei University School of Medicine, Tokyo, Japan.
Yohei SatoDivision of Gene Therapy, Research Center of Medical Sciences, Jikei University School of Medicine, Tokyo, Japan.
Masako FujiwaraDepartment of Pediatrics, Jikei University School of Medicine, Tokyo, Japan.
Nei FukasawaDepartment of Pathology, Jikei University School of Medicine, Tokyo, Japan.
Takahiro FukudaDivision of Neuropathology, Department of Pathology, Jikei University School of Medicine, Tokyo, Japan.
Hiroyuki TakahashiDepartment of Pathology, Jikei University School of Medicine, Tokyo, Japan.
Masahiro IkegamiDepartment of Pathology, Jikei University School of Medicine, Tokyo, Japan.
Motomichi KosugaDivision of Medical Genetics, National Center for Child and Development, Tokyo, Japan.
Torayuki OkuyamaDivision of Medical Genetics, National Center for Child and Development, Tokyo, Japan.
Yoshikatsu EtoAdvanced Clinical Research Center, Institute of Neurological Disorders, Shin-Yurigaoka General Hospital, Kawasaki, Kanagawa, Japan.
Hiroyuki IdaDivision of Gene Therapy, Research Center of Medical Sciences, Jikei University School of Medicine, Tokyo, Japan.
Jikei University School of Medicine · JPNational Center For Child Health and Development · JPMidorigaoka Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report an autopsy case of a woman with mucopolysaccharidosis type I (MPS I) Hurler-Scheie syndrome who was treated with enzyme replacement therapy (ERT) for 12 years. This was the first case of MPS I treated with ERT in Japan. Pathological analysis showed no glycosaminoglycan accumulation in the liver and spleen as a result of long-term ERT, although severe aortic stenosis, diffuse intimal hyperplasia of the coronary artery, and fibrous hypertrophy of the endocardium were observed. Additionally, we detected subunit c mitochondrial ATP synthase (SCMAS) accumulation and mild tauopathy (hyperphosphorylated tau or p-tau, both 3-repeat and 4-repeat tau accumulation) in the same area of the cerebral limbic system and central gray matter of the mid brain and pons. Tauopathy is an important pathological finding in Alzheimer's disease and other neurodegenerative disorders; however, in MPS I, it is unclear whether tauopathy is a primary or secondary phenomenon. Thus, in this report, we describe pathological accumulation of p-tau and SCMAS in the context of MPS I and discuss the mechanisms and importance of these findings in the pathogenesis of MPS I.

Indexed as

AutopsyEnzyme replacement therapyMucopolysaccharidosis type ISubunit c mitochondrial ATP synthaseTauopathy

Identifiers

PMID29705972
PMCPMC6122043
OpenAlexW2799886020

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.